Haipeng Xu

1.1k total citations
43 papers, 454 citations indexed

About

Haipeng Xu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Haipeng Xu has authored 43 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Haipeng Xu's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Haipeng Xu is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Haipeng Xu collaborates with scholars based in China, United States and Hong Kong. Haipeng Xu's co-authors include Gen Lin, Qian Miao, Cheng Huang, Xiandong Lin, Kan Jiang, Yunjian Huang, Dan Hu, Weifeng Zhu, Lin Dong and Wu Zhuang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Haipeng Xu

39 papers receiving 451 citations

Peers

Countries citing papers authored by Haipeng Xu

Since Specialization

Citations

This map shows the geographic impact of Haipeng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haipeng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haipeng Xu more than expected).

Fields of papers citing papers by Haipeng Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haipeng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haipeng Xu. The network helps show where Haipeng Xu may publish in the future.

Co-authorship network of co-authors of Haipeng Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Haipeng Xu. A scholar is included among the top collaborators of Haipeng Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haipeng Xu. Haipeng Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer 2025 ·Thoracic Cancer ·Gen Lin, Yongsheng Wang, Tao Xin, Ding Zhang, Qiuyu Zhang, Yang-Si Li, Yudan Chi, Yun Fan, (unknown), Haipeng Xu, Liang Shi, Longfeng Zhang, (unknown), Xiaobin Zheng, Lijun Li, (unknown), (unknown), (unknown), Kang Miao, Yaping Hong	0
2	Supply and demand of agricultural water resources under future saline-alkali land improvement 2025 ·Agricultural Water Management ·Peng Qi, Bo Li, Dequan Zhang, Haipeng Xu, Guangxin Zhang	3
3	Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. 2025 ·Journal of Clinical Oncology ·(unknown), Jie Wang, Nong Yang, Dongqing Lv, (unknown), Lin Wu, (unknown), (unknown), Yongfeng Yu, Bo Jin, (unknown), Yubiao Guo, Haipeng Xu, Tienan Yi, (unknown), (unknown), Jianhua Chen, Ziping Wang, Tony Mok, Weiguo Su, (unknown)	3
4	1328 SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC): Results from a phase 2 study 2025 ·Lin Wu, Haipeng Xu, Yulan Sun, (unknown), Siyuan Huang, (unknown), Yan Yu, Feng Ye, Dongqing Lv, (unknown), (unknown), Tao Xu, Xingxiang Pu, Xiang Li, Ruoyu Wang, Laiyu Liu, (unknown), Anwen Liu, (unknown), (unknown)	0
5	Natural Staurosporine Derivatives with Fluorescence for Cancer Theranostics 2025 ·ChemMedChem ·(unknown), Wei Liu, (unknown), (unknown), Ying Liu, (unknown), Li Chen, (unknown), Yusheng Lu, Haipeng Xu, Lijun Xie	0
6	Unraveling the Structure–Antioxidant Property Relationship of Lignin: Insights from Botanical Sources and pH-Controlled Fractionation 2025 ·Biomacromolecules ·Kongyan Li, (unknown), Haipeng Xu, Wei Zhong, Yongcan Jin, Min Liu, Wenjuan Wu	1
7	MSSFN: A multi-scale sequence fusion network for CT-based diagnosis of pulmonary complications 2025 ·Neurocomputing ·(unknown), (unknown), Haipeng Xu, (unknown), Huihua Hu, Peishu Wu, Nianyin Zeng	1
8	Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result 2024 ·Scientific Reports ·Yaping Hong, (unknown), (unknown), Haipeng Xu, (unknown), (unknown), Qin Shi, Shengjia Chen, Zhangzhou Huang, (unknown), (unknown), Gen Lin, (unknown)	3
9	Immunotherapy efficacy prediction through a feature re-calibrated 2.5D neural network 2024 ·Computer Methods and Programs in Biomedicine ·Haipeng Xu, Chenxin Li, Longfeng Zhang, Zhiyuan Ding, Tao Lu, Huihua Hu	5
10	Exploring the relationship between lignin structure and antioxidant property using lignin model compounds 2024 ·International Journal of Biological Macromolecules ·Kongyan Li, Haipeng Xu, (unknown), Wei Zhong, Yongcan Jin, Wenjuan Wu	15
11	Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis 2023 ·Journal of Neuro-Oncology ·Yaping Hong, Qian Miao, (unknown), Yiquan Xu, Yunjian Huang, Shengjia Chen, Zhangzhou Huang, Haipeng Xu, Kan Jiang, Qiaofeng Zhong, Longfeng Zhang, Xiaobin Zheng, (unknown), Shanshan Yang, Yujing Li, Shihui Li, (unknown), Gen Lin	4
12	Hsa_circ_0006692 Promotes Lung Cancer Progression via miR-205-5p/CDK19 Axis 2022 ·Genes ·(unknown), Chen Zeng, Xingguang Luο, Ying Su, Tao Huang, Haipeng Xu, Keyu Lin, (unknown), Lurong Zhang, Gen Lin, Xiandong Lin	12
13	<p>LHX6 Affects Erlotinib Resistance and Migration of <em>EGFR</em>-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling</p> 2020 ·OncoTargets and Therapy ·Qiang Wang, (unknown), Zhiyong He, Ying Su, Lin Dong, Ling Xu, Haipeng Xu, Jinghui Lin	16
14	Simultaneous delivery of anti-miRNA and docetaxel with supramolecular self-assembled “chitosome” for improving chemosensitivity of triple negative breast cancer cells 2020 ·Drug Delivery and Translational Research ·Xianfu Sun, Haipeng Xu, Tao Huang, Chengjuan Zhang, (unknown), Suxia Luo	26
15	Impact of treatment modality on long-term survival of stage IA small-cell lung cancer patients: a cohort study of the U.S. SEER database 2020 ·Annals of Translational Medicine ·(unknown), Yuzhen Zheng, Xiaoqiang Li, Haipeng Xu, Junjie Wang, Wei Wang, Qingyuan Huang, (unknown), Chenxi Zhong, (unknown), Lianxiong Yuan, Sichao Wang, (unknown), Wenyu Zhai, Bentong Yu, Kunshou Zhu	9
16	Asymmetric synthesis of l-phosphinothricin using thermostable alpha-transaminase mined from Citrobacter koseri 2019 ·Journal of Biotechnology ·Dongxu Jia, Zijian Liu, Haipeng Xu, Junliang Li, Jiajia Li, Liqun Jin, Feng Cheng, Zhi‐Qiang Liu, Ya‐Ping Xue, (unknown)	29
17	<p>Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer</p> 2019 ·OncoTargets and Therapy ·Haipeng Xu, Xueyan Chen, (unknown), Jing Zhang, Chao Li, Dianbao Zhang, (unknown)	14
18	Co‐expression of NF‐κB‐p65 and phosphorylated NF‐κB‐p105 is associated with poor prognosis in surgically resectable non‐small cell lung cancer 2018 ·Journal of Cellular and Molecular Medicine ·Gen Lin, Chao Li, Cheng Huang, Wu Zhuang, Yunjian Huang, Haipeng Xu, Qian Miao, Dan Hu	11
19	Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer 2017 ·Scientific Reports ·Haipeng Xu, Gen Lin, Cheng Huang, Weifeng Zhu, Qian Miao, (unknown), Wu B, Xiaobing Zheng, Xiandong Lin, Kan Jiang, Dan Hu, Chao Li	36
20	Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·Chao Li, Cheng Huang, Tony Mok, Wu Zhuang, Haipeng Xu, Qian Miao, (unknown), Weifeng Zhu, Yunjian Huang, Xiandong Lin, Kan Jiang, Dan Hu, Xiaohui Chen, (unknown), Gen Lin	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact